Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.
Shin DY, Park S, Jang E, Kong JH, Won YW, Oh S, Choi Y, Kim JA, Lee SW, Mun YC, Kim H, Kim SH, Rok Do Y, Kwak JY, Kim HJ, Zang DY, Lim SN, Lee WS, Kim DW.
Shin DY, et al. Among authors: lim sn.
Leuk Res. 2024 Aug;143:107542. doi: 10.1016/j.leukres.2024.107542. Epub 2024 Jun 17.
Leuk Res. 2024.
PMID: 38924942